Scholar Rock Holding Corporation (SRRK) Earnings Call Transcripts
Scholar Rock Holding Corporation's Latest Earnings Call - June 9, 2026
In Q2 2026, Scholar Rock Holding Corporation reported significant progress in its myostatin biology programs, particularly with apitegromab for spinal muscular atrophy (SMA). The company is poised for a potential launch in the U.S. and Europe by the end of 2026, pending regulatory approval. Revenue and earnings specifics were not disclosed, but the focus was on the strategic advancements and regulatory updates. Management highlighted the successful Phase III trial results and the ongoing regulatory review process, which could significantly impact the stock if approvals are granted. No changes to financial guidance were mentioned.
Reported metrics
| Metric | Value |
|---|---|
| FDA Action Date | September 30, 2026 (neutral) |
| SMA Global Market Size | $5 billion (neutral) |
| Potential SMA Patients | 35,000 (neutral) |
| Phase III Trial Results | 4x improvement likelihood (beat) |
Guidance from management
Management expects to launch apitegromab in the U.S. and Europe by the end of 2026, pending FDA approval. No specific financial guidance was provided.
What management said
That's exactly right. So the OVAL study is really our obligation, more than maybe a commercial opportunity. It's really our obligation of the SMA community to make sure that we understand the youngest patients living with SMA, what the role of apitagrumab is. And so that study is ongoing. We would expect after approval and when we generate data, the PK/PD data, the safety data is all going to be very important for th...
What analysts pressed on
Analysts expressed concerns about the regulatory approval process, particularly the compliance issues at the Catalent Indiana facility. There were also questions about the potential delays in reimbursement and access due to the Medicaid-dominant population.
Main topics on the call
- Apitegromab Phase III Success — Scholar Rock's apitegromab demonstrated a 'statistically significant and clinically meaningful benefit in motor function' in SMA patients, with a 4x greater likelihood of improvement compared to SMN-targeted therapies al...
- Regulatory Progress — The company has resubmitted its BLA for apitegromab, with a new FDA action date of September 30, 2026. Two fill/finish facilities are now included to mitigate previous compliance issues.
- Market Opportunity — Management emphasized the large market potential with approximately 35,000 global SMA patients and a $5 billion market size, highlighting apitegromab's unique position as the only muscle-targeted therapy.
- FSHD Program Initiation — Scholar Rock plans to start a Phase II trial for opitacrumab in FSHD, targeting muscle improvement as a monotherapy or in combination with DUX4 correctors.
Read the full Scholar Rock Holding Corporation transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation (SRRK) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 39 calls on record spanning May 29, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 39 Scholar Rock Holding Corporation earnings call transcripts on record, spanning May 29, 2020 to August 6, 2026. Based on this history, Scholar Rock Holding Corporation reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SRRK
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 39
- First call
- May 29, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly